Our findings of SOX18 inhibition using the novel K-ECFCLYs in vivo model and the success of propranolol, an FDA-approved drug and a SOX18 inhibitor, in treating classic KS encourage further investigations on the use of specific SOX18 inhibitors as a future KS therapy [39]. Here, SOX18 is linked to Kaposi's sarcoma.